Tel: 01789 267520

Nusinersen Expanded Access Programme - What You Can Do To Help

17 March 2017

While we wait for the European Medicines Agency (EMA) to complete its review of the application from Biogen for a licence for nusinersen in Europe, our focus, along with the SMA Trust, is on trying to get NHS England to agree a potential commissioning framework to support the provision of this new and first treatment for SMA. In the short term this would be so that eligible children with SMA Type 1 can access the drug via the Expanded Access Programme (EAP). At the same time this would establish a longer term potential framework for access to the treatment by others affected by SMA.

To support these efforts, you can contact your local MP using the template letter you will find here. Please do add your own experience and circumstances to the letter.

To find out more about nusinersen and recent research updates, please click here. You can also follow our Facebook, Twitter and Instagram pages and sign up to receive our monthly E-news updates here.